Telo Genomics Corp (TSE:TELO)
:TELO
Top Page
Telo Genomics Corp
(TELO)
Select Model
Select Model
Rating:43Neutral
Price Target:
C$0.05
▲(27.50% Upside)
Action:ReiteratedDate:03/05/26
The score is primarily weighed down by weak financial performance (no revenue, ongoing losses and cash burn, and negative equity), which elevates financing and dilution risk. Technicals add a secondary headwind with price trading below major moving averages, while valuation is difficult to support given negative earnings and no dividend yield.
Positive Factors
Proprietary telomere technology
Telo Genomics’ core proprietary telomere measurement platform creates a durable technical differentiation for diagnostic and prognostic applications, supporting entry barriers into clinical and lab channels. That IP focus aids long-term commercial partnerships, licensing, and recurring lab adoption potential.
Negative Factors
No commercial revenue
The company reports no revenue across annual periods and TTM, meaning the core business model is not yet commercially validated. Without sales, margins, customer traction, and repeatable revenue streams remain unproven, increasing execution risk and reliance on external funding to reach commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary telomere technology
Telo Genomics’ core proprietary telomere measurement platform creates a durable technical differentiation for diagnostic and prognostic applications, supporting entry barriers into clinical and lab channels. That IP focus aids long-term commercial partnerships, licensing, and recurring lab adoption potential.
Read all positive factors
Telo Genomics Corp (TELO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$5.32M
Dividend YieldN/A
Average Volume (3M)29.30K
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue GrowthN/A
EPS Growth19.05%
CountryCA
Employees8
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding100,430,470
10 Day Avg. Volume22,350
30 Day Avg. Volume29,304
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)18.74
Price to Sales (P/S)0.00
P/FCF Ratio-4.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Telo Genomics Corp Business Overview & Revenue Model
Company Description
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnos...
How the Company Makes Money
null...
Telo Genomics Corp Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2023 | Jun 2022 | Sep 2020 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -25.57K | -14.45K | -39.54K | -33.11K | -62.23K | -64.72K |
| EBITDA | -2.57M | -2.69M | -2.67M | -2.78M | -1.01M | -1.15M |
| Net Income | -2.62M | -2.72M | -2.71M | -2.82M | -1.07M | -1.24M |
Balance Sheet | ||||||
| Total Assets | 337.79K | 911.30K | 965.64K | 2.93M | 3.84M | 1.17M |
| Cash, Cash Equivalents and Short-Term Investments | 50.11K | 789.29K | 796.02K | 2.67M | 3.64M | 920.98K |
| Total Debt | 161.31K | 0.00 | 0.00 | 32.50K | 40.00K | 40.00K |
| Total Liabilities | 891.12K | 396.32K | 375.59K | 312.87K | 153.66K | 393.42K |
| Stockholders Equity | -553.33K | 514.98K | 590.06K | 2.61M | 3.69M | 775.25K |
Cash Flow | ||||||
| Free Cash Flow | -2.20M | -2.33M | -2.46M | -2.70M | -1.11M | -1.13M |
| Operating Cash Flow | -1.97M | -2.33M | -2.46M | -2.63M | -1.10M | -1.12M |
| Investing Cash Flow | -228.24K | -3.25K | -5.12K | -69.06K | -9.31K | -8.67K |
| Financing Cash Flow | -491.00 | 2.33M | 587.05K | 2.68M | 3.83M | 2.03M |
Telo Genomics Corp Technical Analysis
Neutral
0.04
Price Trends
0.05
Positive
0.05
Positive
0.06
Negative
Market Momentum
<0.01
Negative
50.28
Neutral
116.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TELO, the sentiment is Neutral. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.28 is Neutral, neither overbought nor oversold. The STOCH value of 116.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:TELO.
Telo Genomics Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$63.05M | -32.47 | ― | ― | -21.89% | 26.36% | |
47 Neutral | C$6.58M | -4.67 | -95.29% | ― | -59.28% | -1563.64% | |
43 Neutral | C$5.32M | -2.38 | -9999.00% | ― | ― | 19.05% | |
41 Neutral | C$33.74M | -21.43 | -434.25% | ― | ― | 10.97% | |
41 Neutral | C$5.46M | -3.10 | ― | ― | ― | ― |
* Healthcare Sector Average
TSE:TELO
Telo Genomics Corp
0.05
-0.05
-47.00%
TSE:BUX
BioMark Diagnostics
0.60
0.34
130.77%
TSE:SZLS.H
StageZero Life Sciences Ltd
0.04
0.00
0.00%
TSE:KNE
Kane Biotech
0.03
-0.07
-70.00%
TSE:SONA
Sona Nanotech Inc
0.30
0.03
13.46%
TSE:AVCR
Avricore Health
0.07
0.02
44.44%
Telo Genomics Corp Corporate Events
Business Operations and StrategyExecutive/Board Changes
Telo Genomics Installs New CEO and Chairman as It Prepares for Pivotal Oncology Milestones
Positive
Mar 31, 2026
Telo Genomics Corp. has appointed audit committee chair John Farlinger as its new chief executive officer and chairman, succeeding founder Sabine Mai, who remains on the board. Farlinger, a seasoned public markets and technology executive, receive...
Private Placements and Financing
Telo Genomics Raises $1.39 Million in Final Convertible Debenture Tranche
Positive
Mar 9, 2026
Telo Genomics Corp. has closed the second and final tranche of its non-brokered private placement of secured convertible debentures, raising $545,000 and bringing total proceeds from the offering to $1,385,000. The debentures carry a 15% annual in...
Business Operations and StrategyPrivate Placements and Financing
Telo Genomics Upsizes Convertible Debenture Financing to $1.6 Million
Positive
Feb 27, 2026
Telo Genomics Corp. has increased its previously announced non-brokered private placement of secured convertible debentures from up to $1.2 million to up to $1.6 million, offering 15% annual interest, conversion at $0.05 per share, and detachable ...
Private Placements and Financing
Telo Genomics Raises $840,000 in First Tranche of Convertible Debenture Financing
Positive
Feb 19, 2026
Telo Genomics Corp. has closed the first tranche of a non-brokered private placement of secured convertible debentures, raising gross proceeds of $840,000. The debentures carry 15% annual interest, mature on December 15, 2026, and are convertible ...
Business Operations and StrategyExecutive/Board Changes
Telo Genomics Strengthens Finance Team With Appointment of Veteran CFO John Price
Positive
Jan 29, 2026
Telo Genomics Corp. has appointed John Price as its new Chief Financial Officer, effective January 30, 2026, bringing more than 30 years of experience in accounting operations, financial planning, MA and capital markets, including executive roles ...
Business Operations and StrategyPrivate Placements and Financing
Telo Genomics Seeks Up to $1.2 Million via Convertible Debenture Financing
Positive
Jan 19, 2026
Telo Genomics Corp. has launched a non-brokered private placement of secured convertible debentures to raise up to $1.2 million, offering 15% annual interest with a nine-month term and a conversion price of $0.05 per share, along with detachable w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.